Cencora (COR) Q2 2026 Earnings Transcript

Cencora reported adjusted diluted EPS of $4.75, up 7.5%, and raised full-year EPS guidance to $17.65-$17.90 while maintaining $3 billion free cash flow guidance. However, consolidated revenue growth guidance was cut to 4%-6% from 7%-9% due to slower GLP-1 growth, faster-than-expected brand conversions, and prior customer losses. The quarter also showed margin improvement, with gross profit up 16% and gross margin expanding 45 bps to 4.31% on the OneOncology acquisition, supporting a planned $1 billion share repurchase program.

Analysis

The key takeaway is not the modest guide raise; it’s the mix shift in where earnings are coming from. Cencora is increasingly monetizing scarce specialty capacity, MSO integration, and international execution while accepting that parts of the U.S. channel will become more volatile on revenue but less sensitive on profit. That matters because it makes headline top-line deceleration a poor proxy for intrinsic earnings power: the company is trading low-margin pass-through volume for higher-quality profit pools and buyback capacity.

The biggest second-order effect is that faster biosimilar and brand conversion is likely to accelerate the erosion of distributable revenue dollars while leaving operating income much more resilient than sell-side models assume. In other words, the market may be over-anchoring on revenue growth revisions and underestimating how much of the lost gross billings are structurally low margin or even margin-neutral, especially as Part B specialty offsets Part D channel leakage. The OneOncology/RCA integration adds another layer: if shared services and referral capture scale, the MSO platform could become an earnings multiple rerating story rather than just an acquisition accretion story.

The risk is that the stock can still de-rate if investors conclude the company’s organic U.S. growth has structurally slowed into a 4%-6% revenue world, even if EPS remains on track. That creates a near-term mismatch: strong cash generation, buybacks, and operating profit guidance versus a narrative of fading growth. The cleaner catalyst is the next two quarters, where lapping the oncology loss and OneOncology accretion should make the earnings trajectory visibly improve; if that ramp is delayed, the market may keep discounting the quality of the guide raise.

Bottom line: this is a good setup for a quality/defensive compounder trade rather than a fast-growth trade. The asymmetry is better than the headline suggests because the company is buying back stock into a period of temporary revenue noise while its economics are actually improving.

Key Decisions for Investors

• Long COR vs short a basket of lower-quality healthcare distributors for 3-6 months: the market is likely over-discounting revenue deceleration while underpricing EPS durability and buybacks.
• Buy COR on 2-4% pullbacks, targeting a 6-9 month re-rating as the OneOncology accretion ramp becomes visible and U.S. comp pressure laps; stop if management re-cuts EPS or FCF guidance.
• Pair trade: long COR / short a high-multiple healthcare services name with weaker cash conversion, to express the view that cash-rich compounders will outperform guide-cutters with better growth optics.
• If using options, consider a 6-9 month COR call spread to capture limited near-term upside compression from revenue fears while retaining upside if the market shifts focus to margin quality and capital returns.
• Avoid shorting COR into this print; the combination of FCF, buybacks, and guided operating income growth makes the risk/reward skew unfavorable for a bearish position unless U.S. specialty volumes materially deteriorate.